Applying New Stem Cell Science to Reboot the Immune System

Magenta Therapeutics is a biotechnology company developing therapeutics to revolutionize bone marrow transplant for patients with autoimmune diseases, blood cancers and genetic diseases. By creating a platform focused on critical areas of transplant medicine, Magenta Therapeutics is pioneering an integrated approach to extend the curative power of bone marrow transplant to more patients.

Year Invested: 2016
Location: Cambridge, Mass.

Recent News

April 9, 2018
Magenta Therapeutics Secures $52 Million in Series C Financing

April 5, 2018
Magenta Therapeutics Announces First Patient Transplanted with MGTA-456 in Phase 2 Study in Inherited Metabolic Disorders

April 3, 2018
Magenta Therapeutics Announces Departure of Chief Operating Officer Bastiano Sanna, Ph.D.

Read More News

Associated Team Members

Alexis Borisy